Kontadakis GA, et al. - The impact of nepafenac 0.3% in a once daily dosage regarding pain and healing following photorefractive keratectomy (PRK) for the correction of low to moderate myopia and myopic astigmatism was investigated herein. With regard to pain and ocular discomfort, nepafenac 0.3% ophthalmic suspension in a daily regimen following PRK was an effective treatment, with effects similar to the 0.1% suspension.